Daniel Ebner
Associate Professor/PI and Member of congreation
Daniel Ebner is an Associate Professor and Principal Investigator at the University of Oxford and heads the TDI High Throughput Cellular Screening Facility and the Oxford CRISPR/Cas9 Screening Facility at the Target Discovery Institute (TDI), Centre for Medicines Discovery, Nuffield Department of Medicine. Daniel’s main academic research, through a five year £7M CRUK funded grant in collaboration with researchers from the University of Edinburgh and MIT, is focused on identifying and advancing novel combinatorial therapeutics for the treatment of glioblastoma. As head of the cellular screening facility, Daniel has worked with academic and industrial collaborators to complete >150 research projects and has published >70 peer-reviewed papers in the past 5 years in high impact journals such as the Lancet, New England Journal of Medicine, Nature and Journal of the American Medical Association across a broad range of pathologies including on neurodegeneration, inflammation, autophagy, large-scale iPSC CRISPR/Cas9 screening methods, and novel more physiologically relevant screening models. Previous to his academic career at the University of Oxford, Daniel has worked for >10 years in the biotechnology and pharmaceutical industry.
Recent publications
-
Selective ROCK Inhibitor Enhances Blood Flow Recovery after Hindlimb Ischemia
Journal article
Fayed HS. et al, (2023), International Journal of Molecular Sciences, 24, 14410 - 14410
-
Chemogenomic library design strategies for precision oncology, applied to phenotypic profiling of glioblastoma patient cells
Journal article
Athanasiadis P. et al, (2023), iScience, 26
-
COVID-19 vaccination, risk-compensatory behaviours, and contacts in the UK.
Journal article
Buckell J. et al, (2023), Sci Rep, 13
-
Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK.
Journal article
Wei J. et al, (2023), Nat Commun, 14
-
Data from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Other
Rodriguez-Berriguete G. et al, (2023)